Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Moodys
Covington
McKinsey
Deloitte
QuintilesIMS
Citi
Federal Trade Commission
Merck
Cantor Fitzgerald

Generated: October 23, 2017

DrugPatentWatch Database Preview

RELPAX Drug Profile

« Back to Dashboard

Which patents cover Relpax, and what generic Relpax alternatives are available?

Relpax is a drug marketed by Pfizer Ireland and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty patent family members in forty-six countries and four supplementary protection certificates in four countries.

The generic ingredient in RELPAX is eletriptan hydrobromide. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the eletriptan hydrobromide profile page.

Summary for Tradename: RELPAX

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list6
Bulk Api Vendors: see list28
Clinical Trials: see list3
Patent Applications: see list176
Drug Prices:see details
DailyMed Link:RELPAX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002ABRXYesYes► Subscribe► Subscribe ► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002ABRXYesNo► Subscribe► Subscribe ► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RELPAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002► Subscribe► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002► Subscribe► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002► Subscribe► Subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for RELPAX

Drugname Dosage Strength RLD Submissiondate
eletriptan hydrobromideTablets20 mg and 40 mgRelpax3/29/2010

Non-Orange Book Patents for Tradename: RELPAX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,559,129 Indole derivatives► Subscribe
6,380,226 Salts of an anti-migraine indole derivatives► Subscribe
5,578,612 Indole derivatives► Subscribe
5,559,246 Indole derivatives► Subscribe
5,607,951 Indole derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RELPAX

Country Document Number Estimated Expiration
Morocco23650► Subscribe
Hungary9503089► Subscribe
Egypt20224► Subscribe
Denmark0776323► Subscribe
Slovakia24897► Subscribe
New Zealand240217► Subscribe
Turkey9501061► Subscribe
European Patent Office0696194► Subscribe
China1509713► Subscribe
Finland113768► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RELPAX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0013France► SubscribePRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214
/2001Austria► SubscribePRODUCT NAME: ELETRIPTAN UND DIE PHARMAZEUTISCH VERTRAEGLICHEN SALZE DAVON, EINSCHLIESSLICH DES HYDROBROMIDS; NAT. REGISTRATION NO/DATE: 1-24155 20010801; FIRST REGISTRATION: LI 55218 01, 55218 02 20001214
C/GB01/023United Kingdom► SubscribePRODUCT NAME: ELETRIPTAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE HYDROBROMIDE SALT; REGISTERED: CH 55218 01 20001214; CH 52218 02 20001214; CH 52218 03 20001214; UK PL 00057/0452 20010212; UK PL 00057/0453 20010212; UK PL 00057/0454 20010212
0592438/01Switzerland► SubscribeFORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Queensland Health
Medtronic
Cipla
AstraZeneca
Merck
Deloitte
Harvard Business School
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot